- Pharmaceutical Executive: December 2024
- Volume 44
- Issue 12
Trending Forward
Complementing our own industry trends and outlook coverage this month are a trio of diverse crystal-ball perspectives from guest thought leaders.
It’s that time of year again, when, as one often does, a peek into next year is in order. While making holiday plans with friends and family and wrapping gifts is, of course, on the agenda, it doesn’t stop the wonder and anticipation of what may lie around the corner in our own lives and in the world from building. The same goes for the pharma industry. And to that end, here at Pharmaceutical Executive, we decided to switch things up a bit in our coverage planning, moving our Annual Industry Outlook feature from its usual spot—the first issue of the new year—to right here in December, as a fitting capper to an event-filled 2024 for pharma and healthcare. Because, after all, you can’t properly look ahead without taking stock of what came before.
Editors of Pharm Exec do both in our
Complementing our own trends coverage this month are a trio of crystal-ball perspectives from guest thought leaders. The
“While US sales projections often form the backbone of global forecasts, extrapolating these figures without accounting for the unique characteristics of other markets introduces significant risks and errors,” the authors write.
The
Not to be outdone on the outlook front is our
Here’s to ushering in the new and building on the old. Have a wonderful, safe, and happy holiday season!
Mike Hennessy Jr. is President and CEO of MJH Life Sciences
Articles in this issue
10 months ago
Pharmaceutical Executive: December 2024 Issue (PDF)10 months ago
Pharma’s ‘Best-Kept Secret’10 months ago
Seeking More Value, Less Cost10 months ago
Dealmaking Dormant No More10 months ago
A Rocky Road for Regulation10 months ago
DTC's New Era of Engagement10 months ago
Holding On Tight to AI WaveNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.